Dr. Xiaosong Li 李晓松
Chief Physician, Associate Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Targeted and immunotherapy for lung, breast, colorectal, and gastric cancers. Integrates laser therapy, hyperthermia, and radiotherapy to enhance treatment efficacy.
Dr. Li is a Chief Physician and Associate Professor at the First Medical Center of Chinese PLA General Hospital. A Beijing Science and Technology Star and state-sponsored visiting scholar, Dr. Li serves as a master’s supervisor for several universities. Research includes leading one National Key R&D Program project and three National Natural Science Foundation projects. Publications include 74 papers (33 SCI/EI indexed), one edited monograph, and three patents.
Professional roles
- Member, Chinese Medical Association
Name order: in Chinese the family name comes first (Li Xiaosong). Papers usually list the name as Xiaosong Li or Li X.
Selected publications
40 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Nanomedicine, 2026 (senior author): Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation. PubMed 42609883
- J Thorac Oncol, 2026 (first author): Exploring the Continuum of HER2 TKD Mutations and HER2 "Sensitizing Mutations" in NSCLC and Retiring the Term "HER2 Exon 20 Insertions". PubMed 42552031
- Redox Biol, 2024 (senior author): SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors. PubMed 39153252
- BMC Med Genomics, 2023 (senior author): Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma. PubMed 37553698
- Technol Cancer Res Treat, 2023 (senior author): Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers. PubMed 36734039
- Front Oncol, 2022 (senior author): Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence. PubMed 35712471
- Cancer Control, 2021 (senior author): Research Progress of Autofluorescence Imaging Technology in the Diagnosis of Early Gastrointestinal Tumors. PubMed 34569317
- Ther Adv Respir Dis, 2020 (senior author): Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report. PubMed 32600123
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion